Cannabinoid Sol-Gel Delivery
Nose-to-Brain Delivery of Therapeutic Cannabinoids
Developing the first, sustained-release, cannabinoid-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders. Our proprietary nasal formulations will also be designed to be universally-patient friendly, meaning formulations that can be used in children and adults alike.
Sol-gels are taken via nasal administration and rapidly gel upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This effectively bypasses the stomach and intestines - eliminating first pass metabolism - and may dramatically improve bioavailability - even compared to nasal sprays and other newer delivery systems. Additionally, the gel stays in the nasal passages, slowly releasing the cannabinoid while keeping it active for up to seven days. The ease of application and its long-lasting effects may be attractive for patients when compared to other delivery systems.
COVID-19 CBD Sol-Gel Program
PreveCeutical elected to extend this program in July 2020 to address the current COVID-19 pandemic. Under this extension, a nasal formulation incorporating a cannabinoid extract has been created. This formulation is based on reports by independent researchers who identified this extract as having anti-inflammatory properties and the potential to reduce the ability of SARS-CoV-2 to infect mucosa tissue.
We completed this development in November 2020, and PreveCeutical has filed a provisional patent. The Company will be looking to commercialize this formulation as a nasally administered treatment for COVID- 19 caused by SARS-CoV-2 infection.
PreveCeutical has also retained Versitat, a global clinical research organization, to assist with the clinical trial process. They have developed the roadmap, and clinical trial planning is underway.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.
PreveCeutical now plans to begin exploratory discussions with pharmaceutical and biotechnology companies developing therapies for neurological disorders, that are seeking a targeted nose-to-brain drug delivery system in connection with same, with the intention of forming a partnership for the co-development of PreveCeutical's soluble gel.
"Sol-gel technology has certainly shown significant promise in laboratory testing at this point. eventually, I would like to see this proprietary technology be successfully applied to a drug which could be targeted for CNS delivery at the right time, we would welcome an opportunity to work with a pharmaceutical or biotechnology company to co-develop the Sol-Gel and sol-gel Applicator to be used in pharmaceutical and therapeutic products." – Chief Science Officer: Dr. Mak Jawadekar, PhD.